# Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer

> **NCT07714447** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 91 (estimated)

## Conditions studied

- CRC (Colorectal Cancer)
- BRAF

## Interventions

- **DRUG:** Arm1
- **DRUG:** Arm 2
- **DRUG:** Arm 3

## Key facts

- **NCT ID:** NCT07714447
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-30
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-02-26
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07714447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07714447, "Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07714447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*